RAB27A and prostate cancer: All mice injected with the control prostate cancer cells developed visible tumors within 35 days, whereas mice with Rab27a-null and PD-L1-null cells showed no tumor growth during the same time period and had significantly longer survival periods [50], supporting PD-L1 targeting as a viable therapeutic strategy.